Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of high-risk myelodysplastic syndromes with cytarabine + bortezomib
2005-005794-29Phase 2Completed
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Jan 2006
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib and cytarabine in myelodysplastic syndrome (MDS), sponsored by Groupe Français des Myélodysplasies. Primary endpoint: hematological response at week 16. Started Jan 2006; status: completed.
02
Drugs
bortezomibcytarabine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2005-005794-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005794-29.